Virtual Library
Start Your Search
Yuki Tanaka
Author of
-
+
EP1.04 - Immuno-oncology (ID 194)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.04-26 - Efficacy and Safety of Anti-PD-1 Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer (Now Available) (ID 2107)
08:00 - 18:00 | Presenting Author(s): Yuki Tanaka
- Abstract
Background
Recently, the proportion of elderly patients with advanced non-small cell lung cancer (NSCLC) has increased. However, those patients cannot occasionally continue to receive systemic therapy due to adverse events (AEs) or decreased performance status (PS). There are few reports which address efficacy and safety of anti-PD-1 inhibitors as the second line therapy for such elderly patients. The purpose of this study is to evaluate the efficacy and feasibility of anti-PD-1 inhibitors for elderly patients with advanced NSCLC are controversial.
Method
We retrospectively evaluated the efficacy and feasibility of anti-PD-1 inhibitors in 14 elderly patients (≥ 75 years old) with advanced NSCLC, comparing with 53 non-elderly patients (< 75 years old). All patients received anti-PD-1 inhibitors as the second line therapy or later.
Result
Of the 14 elderly patients, 11 patients had PS score 0 or 1. Anti-PD-1 inhibitors included nivolumab in 11 patients and pembrolizumab in 3 patients, and the median courses of anti-PD-1 inhibitors was 7 (1-27). There was no difference in patient background between the elderly group and the non-elderly group. The objective response rate (ORR) was 43% in the elderly group, while the rate was 30% in the non-elderly group (p = 0.33). The median progression-free survival (PFS) was 12.1 and 11.1 months in the elderly and non-elderly group, respectively (p = 0.86). The median overall survival (OS) was 14.3 and 29.6 months in the elderly and the non-elderly group, respectively (p = 0.53). Immune related AEs (irAEs) of grade 2 or higher were significantly observed in 50% of the elderly group, comparing with 17% of the non-elderly group (p = 0.048).
Conclusion
The anti-PD-1 inhibitors led to good prognosis for the elderly patients with advanced NSCLC while the rate of irAEs was higher. The follow-up or management of irAE should be careful.
